From Indolent to Aggressive

Program Overview

Systemic mastocytosis (SM) is a complex and often misdiagnosed condition that can affect multiple organ systems and cause symptoms ranging from anaphylaxis to bone pain and gastrointestinal distress. This interactive Case-in-Point™ CME symposium will feature real-world case discussions, audience polling, and expert insights to help clinicians navigate the challenges of diagnosing and managing both nonadvanced and advanced SM. Expert faculty will review updated diagnostic criteria, emerging and FDA-approved treatment strategies, and provide practical guidance on monitoring treatment response, addressing persistent symptoms, and engaging patients in shared decision-making. Whether you are new to SM care or looking to refine your approach, this session will enhance your confidence and equip you with practical strategies to optimize care for patients across the SM spectrum.

Join us for this engaging session designed to strengthen your skills in delivering high-quality, personalized care for patients with SM!

Target Audience

The educational design of this activity addresses the needs of hematology/oncology (hem/oncs) and hematopathology specialists.

Educational Objectives

After completing this activity, participants will be better prepared to:

1. Differentiate nonadvanced and advanced SM subtypes using WHO and ICC diagnostic criteria, symptom profiles, biomarkers, and molecular testing, including high-sensitivity assays
2. Explain the pathophysiologic mechanisms of SM, including the role of KIT D816V and other mutations in driving mast cell proliferation, disease severity, and progression risk
3. Interpret the latest clinical trial data and safety/efficacy evidence for FDA-approved and investigational therapies used across the SM spectrum
4. Develop individualized, multidisciplinary treatment and monitoring strategies that incorporate disease subtype, symptom burden, shared decision-making, PROs, and coordination across specialties

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must attend the live program and complete the posttest and program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

All relevant financial relationships have been mitigated. The faculty have the following relevant financial relationships with ineligible companies:

• Brian Chernak, MD Consulting Fees: Cogent Biosciences, Geron Corporation, Sobi
• Matthew P. Giannetti, MD Consulting, Medical Safety Board: Cogent Biosciences, Inmagene; Research Funding: Blueprint Medicines Corporation
• Tsewang Tashi, MD Consulting Fees: Blueprint Corporation, Cogent Biosciences, PharmaEssentia

The Integritas Communications planners and managers have no relevant financial relationships to disclose.

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

The Integritas Communications planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.